Xerava is owned by Tetraphase Pharms.
Xerava contains Eravacycline Dihydrochloride.
Xerava has a total of 3 drug patents out of which 0 drug patents have expired.
Xerava was authorised for market use on 27 August, 2018.
Xerava is available in powder;intravenous dosage forms.
Xerava can be used as treatment of complicated intra-abdominal infections in patients 18 years of age and older.
Drug patent challenges can be filed against Xerava from August, 2027.
The generics of Xerava are possible to be released after 19 October, 2037.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US10961190||TETRAPHASE PHARMS||Crystalline forms of eravacycline|| |
(14 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8796245||TETRAPHASE PHARMS||C7-fluoro substituted tetracycline compounds|| |
(6 years from now)
|US8906887||TETRAPHASE PHARMS||C7-fluoro substituted tetracycline compounds|| |
(7 years from now)
|New Chemical Entity Exclusivity (NCE)||Aug 27, 2023|
|Generating Antibiotic Incentives Now (GAIN)||Aug 27, 2028|
NCE-1 date: August, 2027
Market Authorisation Date: 27 August, 2018
Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic